Immunic Psoriasis Analysis Adds Dose Of Uncertainty To Program
Executive Summary
Without disclosing full Phase Ib data, the company reported a higher-than-expected placebo response versus IMU-935. With its second setback this year Immunic has a long path to meaningful data.
You may also be interested in...
Immunic Doubles Down On Lead Asset With New Data In Ulcerative Colitis
The company is emphasizing development of vidofludimus calcium in multiple indications and deprioritizing izumerogant, an asset the company was developing in psoriasis and prostate cancer.
Syndax Readies FDA Filing In Leukemia After Stopping Revumenib Trial Early For Efficacy
The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.
Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.